WuXi AppTec's fourth straight year in the FTSE4Good Index highlights its sustained ESG leadership and may boost appeal to sustainability‑focused investors
Executive summary: WuXi AppTec announced it has been named a constituent of the FTSE4Good Index Series for the fourth consecutive year. The inclusion signals sustained strong environmental, social and governance performance, which can attract ESG‑focused capital and potentially lower financing costs.
Who is involved: WuXi AppTec (a global pharmaceutical CRDMO), FTSE Russell (index provider).
Likely next: The company will remain subject to FTSE4Good's periodic reviews, which determine continued eligibility.
WuXi AppTec announced that it has been retained as a constituent of the FTSE4Good Index Series for the fourth consecutive year. The index measures companies against environmental, social and governance criteria, and continued inclusion reflects the firm’s ongoing compliance with those standards. The recognition is a signal to ESG‑oriented investors and partners that the CRDMO maintains a strong sustainability profile.
Timeline
- — WuXi AppTec Named Constituent of the FTSE4Good Index Series for Fourth Consecutive Year (PR Newswire)
- — WuXi Biologics' MFG8 Drug Substance Facility Secures FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy (PR Newswire)
Analysis — what this means
Sectors affected
- pharmaceutical contract research, development and manufacturing (CRDMO)
- ESG investment funds
Historical parallels
- WuXi AppTec was also a FTSE4Good constituent in 2023, 2024 and 2025 (three prior consecutive years)
Key entities
Sources
- WuXi AppTec Named Constituent of the FTSE4Good Index Series for Fourth Consecutive Year — PR Newswire
- WuXi Biologics' MFG8 Drug Substance Facility Secures FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy — PR Newswire
Related cases
- WuXi AppTec raises its 2026 interim dividend to RMB 1.51 billion, returning more cash to shareholders amid strong half‑year results
- WuXi Biologics earns top sustainable biopharma recognition, underscoring its green CRDMO leadership
- WuXi XDC’s GMP‑cleared BCM3 facility in Singapore expands its bioconjugate manufacturing capacity, positioning the CDMO to capture additional global contract work
- WuXi Biologics earns sixth straight FTSE4Good inclusion, highlighting its green CRDMO sustainability leadership
- InfiMotion Technology debuts its E Drive electric propulsion system in Wuxi, signaling readiness for EV market engagement
- InfiMotion Technology’s public debut in Wuxi highlights its full E‑drive system capabilities and marks its entry as an independent electric‑vehicle drivetrain supplier